» Articles » PMID: 19698914

Mohs Micrographic Surgery for the Management of Nonmelanoma Skin Cancers

Overview
Specialty General Surgery
Date 2009 Aug 25
PMID 19698914
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Many treatment modalities have been described to address the growing epidemic of nonmelanoma skin cancer (NMSC). Mohs micrographic surgery (MMS) is a surgical technique that allows complete and precise microscopic margin analysis by using horizontal frozen sections. The purpose of MMS is twofold: to ensure definitive excision and to minimize loss of normal surrounding tissue. MMS offers the advantages of superior cure rates and, because tissue removal is minimized, excellent cosmetic outcomes. Therefore, MMS has become the treatment of choice for many high-risk tumors. Because this technique is labor intensive, MMS is not indicated in certain situations. Understanding the indications, advantages, and disadvantages of MMS remains paramount for facial plastic surgeons managing NMSC.

Citing Articles

[Diagnosis and treatment monitoring of basal cell carcinoma in one step: BCC one-stop shop : In vivo and ex vivo monitoring of basal cell carcinoma margins].

Schuh S Dermatologie (Heidelb). 2024; 75(7):587-591.

PMID: 38935289 DOI: 10.1007/s00105-024-05378-9.


Unveiling the hidden boundaries: AI-assisted line-field optical coherence tomography margin mapping for precise excision of basal cell carcinoma - A step-by-step tutorial.

Deussing M, Eijkenboom Q, Thamm J, Desch A, Funfer K, Mozaffari M Skin Res Technol. 2024; 30(2):e13594.

PMID: 38297955 PMC: 10831192. DOI: 10.1111/srt.13594.


Use of Intraoperative Frozen Section in the Surgical Management of Patients with Nonmelanoma Skin Cancer.

Loh L, Tiwari P, Lee J, Low O, Nallathamby V, Lee H J Skin Cancer. 2021; 2021:4944570.

PMID: 34760320 PMC: 8575635. DOI: 10.1155/2021/4944570.


Does reduction of the oncologic safety margin for facial basal cell carcinoma result in higher recurrence rates?.

Kim E, Yang C, Chung Y Arch Craniofac Surg. 2021; 22(3):135-140.

PMID: 34225404 PMC: 8257443. DOI: 10.7181/acfs.2021.00206.


Treatment and Outcomes for Cutaneous Periauricular Basal Cell Carcinoma: A 16-Year Institutional Experience.

Peters M, Smith J, Kovatch K, McLean S, Durham A, Basura G OTO Open. 2020; 4(4):2473974X20964735.

PMID: 33150296 PMC: 7580161. DOI: 10.1177/2473974X20964735.